All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
Details:
Primary endpoint was achieved, with dexpramipexole demonstrating a statistically significant reduction in blood eosinophil count over 12 weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Tyvaso
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
United Therapeutics intends to initiate a phase 3 study, called TETON, to evaluate the use of Tyvaso® (treprostinil) Inhalation Solution in patients with IPF.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Deupirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LYT-100
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
LYT-100 is a deuterated, oral small molecule designed to overcome the challenges associated with pirfenidone, an approved and marketed anti-inflammatory and anti-fibrotic drug. Phase 2 trial will evaluate LYT-100 in Long COVID respiratory complications and related sequelae.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Recombinant human plasma gelsolin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Rhu-pGSN
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2020
Details:
The study assesses rhu-pGSN, and its ability to regulate the overactive inflammatory response often responsible for causing lung damage and death in COVID-19 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LTI-01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-01
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Taiho Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 12, 2020
Details:
Under the terms of the agreement, Taiho will obtain the rights for the development and commercialization of LTI-01 in Japan. Lung Tx will receive an upfront payment, milestone, and royalty payments based on product sales.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sotatercept
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ACE-011
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The presentation of the PULSAR trial echocardiography data, which earned the AHA’s “Cardiopulmonary Best Abstract” award, will focus on sotatercept’s effects on cardiac right ventricular function in conjunction with pulmonary arterial pressure in patients with PAH.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Razuprotafib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AKB-9778